Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine from Eli Lilly, as the Danish drugmaker tries to seize market share among consumers paying cash for blockbuster GLP-1 therapies.
Novo will sell the highest doses of its Wegovy pill, cleared last week, at $299 a month for patients paying the company directly, according to the drug’s website. Meanwhile, Lilly has said it plans to sell its weight loss pill orforglipron at up to $399 a month following approval, which is expected in the next few months.
The Wegovy pill’s price is also lower than the prices of injectable drugs when sold directly to patients — $349 for injectable Wegovy and $449 for Lilly’s Zepbound.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
